1 Human skin mast cells, unlike other human mast cells so far studied, released histamine in a concentration-related manner in response to substance P, vasoactive intestinal peptide (VIP) and somatostatin (1 yM to 30 yM). In contrast, eledoisin, physalaemin, neurokinin A, neurokinin B, calcitonin gene-related peptide (CGRP), neurotensin, bradykinin and Lys-bradykinin induced negligible histamine release. 2 The low histamine releasing activity of physalaemin, eledoisin, neurokinin A and neurokinin B relative to substance P suggests that the human skin mast cell activation site is distinct from the tachykinin NK-1, NK-2 or NK-3 receptors described in smooth muscle.
Introduction
The mast cells of human skin are closely associated with both dermal nerve endings and blood vessels (Eady et al., 1979) . Increasing evidence suggests that the secretory function of these cells may be regulated by the nervous system (Goetzl et al., 1985; Foreman, 1987) . Mammalian skin contains a variety of neuropeptides including substance P, vasoactive intestinal peptide (VIP), somatostatin, neurotensin and calcitonin gene-related peptide (CGRP) (Hartschuh et al., 1983; O'Shaughnessy et al., 1983; Brain et al., 1986) all of which are potential mast cell activators. Each of these peptides is capable of inducing a weal and flare reaction when injected intradermally into human skin Anand et al., 1983; Piotrowski & Foreman, 1986 ) and it has been I Author for correspondence. suggested that the vasodilatation and, to a lesser extent, plasma extravasation, are secondary to the release of mast cell mediators (Hagermark et al., 1978; Foreman et al., 1982) . This hypothesis presupposes that neuropeptides can directly or indirectly activate human skin mast cells.
There is some evidence that the ability of neuropeptides to induce weal and flare reactions in human skin is closely correlated to histamine releasing activity from rat peritoneal mast cells (Foreman et al., 1983) . These cells release histamine in response to both IgE-dependent and non-immunological stimuli (Lagunoff et al., 1983) . Non-immunological stimuli include compound 48/80, morphine and the basic peptides substance P. VIP, somatostatin, neurotensin and CGRP (Grosman, 1981; Shanahan et al., 1985; Piotrowski & Foreman, 1986) .
In our studies of mast cells dispersed from human skin, lung, tonsils, colon and adenoids, we established that skin mast cells are unique amongst these in releasing histamine in response to compound 48/80, morphine and substance P (Benyon et al., 1987; Lowman et al., 1988) . In this paper we extend our observations on the ability of neuropeptides to induce histamine release from human skin mast cells and suggest that they activate histamine release by binding via basic moieties to the same, or a closely related, binding site distinct from the IgE-receptor.
Methods

Mast cell dispersion
This was performed using methods similar to those previously described by Benyon et al. (1987) . Samples of foreskin from young children (1-12 years) were placed immediately in MEM following circumcision, stored at 40C, and used within 24h. Fragments of 0.5 to 2.0mm, obtained by chopping with scissors, were washed twice with MEM containing 2.0% FCS (MEM/FCS). In experiments to investigate histamine release induced by anti-IgE, skin slices were passively sensitized by incubation for 2h at 370C in MEM containing 5% FCS and 10% human atopic serum. To disperse mast cells, tissue was incubated for 60min at 370C in MEM (1 g tissue per 10 ml buffer) containing collagenase 1.5 mg ml 1, hyaluronidase 0.75mg ml-1 and BSA 35 mgm Xl'. Dispersed cells were separated from undissociated tissue by filtration through 150ym mesh nylon gauze and were washed twice with MEM/FCS by centrifugation at 5OOg for 5min at 20'C. Undigested tissue was subjected to a second identical digestion and the cells from both were pooled, washed once with MEM/FCS, and mast cell numbers were determined by light microscopy following metachromatic staining with Kimura stain (Kimura et al., 1973) .
Mast cell activation
Before activation for histamine release, cells were washed once in HEPES-BSS by centrifugation at 500g for 5 min at 20°C and were then resuspended in this buffer to a density of approximately 5 x 104 mast cellsml-. After warming to 37°C for 10min, samples of 225 p1 were added to polypropylene tubes containing 25pu1 of secretagogue, and histamine release reactions allowed to continue for 15min before termination by addition of 750 p1 of ice-cold HEPES-BSS and centrifugation at 500 g for 5 min at 40C. All histamine release reactions were performed in duplicate. Supernatant and cell pellet histamine content was determined by automated spectrofluorimetry (Evans et al., 1973) . Net histamine release was calculated as a percentage of total cell-associated histamine following correction for spontaneous release, assessed in duplicate cell samples in the absence of secretagogue. At the secretagogue concentrations used, only somatostatin (10-30.uM) interfered with this assay. Histamine release by somatostatin was corrected for intrinsic fluorescence of the peptide using a series of fluorescence controls.
In experiments to analyse the time course of histamine release, the above procedure was modified as follows. To 180y1 samples of cell suspension prewarmed to 37°C for 10min were added 2Oul of secretagogue. Reactions were stopped at the stated times by addition of 800p1 of ice-cold, calcium-free HEPES-BSS containing 2 mm EDTA and centrifugation at 10OOg for 2min at 4°C. Supernatant and cell associated histamine was measured as described above. As spontaneous histamine release was constant over the time periods used in the time course experiments, a mean value was used to calculate net histamine release.
Calcium deprivation and energy dependence studies
In studies of the effects of calcium deprivation on histamine release, cell preparations were incubated for 5 min at 37°C in calcium-free HEPES-BSS containing 2 mm EDTA before the 15min incubation with secretagogue. To assess the energy dependence of histamine release, cells were incubated for 20 min at 37°C in glucose-free HEPES-BSS containing 10mM 2-deoxy-D-glucose (to inhibit glycolysis) and 1 yM antimycin A (to inhibit oxidative phosphorylation) before the 15 min incubation with secretagogue. Dimethylsulphoxide, used as a solvent for antimycin A to a final concentration of 0.25%, had no significant effect on histamine release.
Substance P antagonist studies
In studies of the effects of [D-Pro4,D-Trp7'9'10] SP-11 on secretagogue-induced histamine release, 200 p1 samples of cell suspension were incubated with 25y1 of antagonist for 5 min at 37°C before addition of 25.p1 of secretagogue. Histamine release reactions were allowed to proceed for 15 min at 37°C before termination as described above.
Materials
The following chemicals and enzymes were used: collagenase (type I), hyaluronidase (type I), deoxy- ribonuclease (bovine pancreas), bovine serum albumin (Fraction V) (BSA), compound 48/80, poly-L-lysine (average mol wt 45,000 to 55,000 daltons), substance P (SP) (Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2), substance P fragment 2-11 (SP2-11), substance P fragment 4-11 (SP4 1J) substance P fragment 1-4 (SP1 4), eledoisin, physalaemin, neurokinin A, neurokinin B, vasoactive intestinal peptide (VIP), somatostatin, neurotensin, bradykinin, Lys-bradykinin, [D-Pro2,D-Trp7'9] substance P. dimethylsulphoxide (DMSO), antimycin A, 2-deoxy-D-glucose, N-2-hydroxyethyl-piperazine-N'-2-ethanesulphonic acid (HEPES) (Sigma Chemical Co., Poole, Dorset); foetal calf serum (FCS), Eagle's minimum essential medium (MEM) containing 25 mM HEPES and L-glutamine (Gibco Europe Ltd., Paisley, Scotland); ethylenediaminetetraacetic acid (EDTA) (BDH Chemicals, Poole, Dorset); substance P fragment 3-11 (SP3_1 t) calcitonin gene-related peptide (CGRP), [D-Pro4,D-Trp7,9'10] SP4-11 (SPA) (Peninsula Laboratories Europe Ltd., St. Helens, Merseyside); morphine sulphate (Evans Medical Ltd., Greenford, Middlesex). Atopic serum used for mast cell passive sensitization was obtained from an individual allergic to Timothy grass pollen. Goat anti-human IgE serum was heat-inactivated by incubation at 60°C for 1h. HEPES-buffered salts solution (HEPES-BSS), pH 7.2, contained (mM) NaCl 137, HEPES 10, D-glucose 5, KCl 2.7, NaH2PO4 0.4, MgCl2 0.5, CaCl2 1.8 and FCS 1.0%, these reagents being of analytical grade.
Statistical analyses
Results are expressed as mean + 1 standard error of mean (s.e.mean) for the stated number of separate experiments. Differences between means were tested for significance using Student's t test for paired data, differences being considered significant when the probability (P) was <0.05.
Results
Histamine releasing activity of peptides In 20 experiments substance P induced a concentration-related release of histamine ( Figure  la) . Release from foreskin mast cells with substance P, 30pm, was 14.8 ± 1.6%, approximately half that released from mast cells obtained from adult breast skin (Lowman et al., 1988) . Histamine release The ability of substance P fragments SP2 11, SP311 and SP4-11 to release histamine from human skin mast cells was compared with that of substance P in 4-7 experiments (Table 1 ). In these experiments progressive removal of N-terminal amino acids reduced histamine releasing activity. Relative potencies of substance P and its fragments calculated from the parallel portions of the concentrationresponse lines were: substance P = 1, SP2-11 = 0.46 and SP341 = 0.16. No potency ratio was calculated for SP4-11 as it only released 3.5 + 0.5% histamine at 30 yM, the maximum concentration used. The basic N-terminal tetrapeptide, SP14, induced no significant histamine release, suggesting that the Cterminal portion is essential for expression of activity. '
Tachykinin receptors on smooth muscle have been 10 30 divided into 3 sub-classes, NK-1, NK-2 and NK-3, stance P (>M) on the basis of relative potencies of eledoisin, physalaemin, neurokinin A and neurokinin B to cause contraction (Lee et al., 1986) . These tachykinins were used to investigate whether the site at which substance P activates skin mast cells falls into such a classification. The results (Table 1) showed that only physalaemin and neurokinin A caused significant concentration-related histamine release and that all were significantly (P < 0.001) less potent than substance P.
Vasoactive intestinal peptide (VIP) induced a concentration-related release of histamine from human skin mast cells (Figure 2a ), reaching 19.3 + 4.0% at 30prm. At no concentration was release induced by VIP significantly different from that induced by substance P in the same experiments. The time course of release, like that of substance P. was rapid, reaching completion within 20s of VIP addition (Figure 2b ). Similar results were obtained with somatostatin ( Figure 3 (Figure lb) . This time-course contrasts with that of IgE-dependent histamine release which reaches a maximum 5-7min after challenge (Benyon et al., 1987) .
The effects ofcalcium deprivation and metabolic inhibitors on histamine release
Challenge of human skin mast cells in calcium-free HEPES-BSS containing 2mm EDTA reduced histamine release induced by 1% anti-IgE to levels not significantly greater than spontaneous in three experiments (Table 2) . Similar results were obtained with nominally calcium-free medium lacking EDTA, suggesting IgE-dependent histamine release to be dependent on the presence of extracellular calcium. In contrast, histamine release induced by VIP and somatostatin was independent of extracellular calcium in three experiments, there being no significant difference between histamine release induced by VIP, 3pM, and somatostatin, 3pm and 1OpM, in the presence and absence of extracellular calcium, Histamine release induced by substance P. 10 yM and 100 yM, was only partially dependent on extracellular calcium. Again, similar results were obtained with nominally calcium-free medium lacking EDTA.
To determine whether histamine release from human skin mast cells induced by substance P, VIP and somatostatin was an energy-dependent process Each result is the mean ± s.e.mean of 3-7 experiments in which cells were incubated in either calcium-free HEPES-BSS containing 2mM EDTA for 5 min or glucose-free HEPES-BSS containing 10mM 2-deoxy-D-glucose and 1 M antimycin A for 20min before activation for histamine release. Histamine release has been corrected for spontaneous release, which was in the range 2.4% to 9.4%, and * denotes results significantly (P < 0.05) different from control. VIP, vasoactive intestinal peptide. and, presumably, non-cytotoxic, four experiments were undertaken in which cellular glycolysis and oxidative phosphorylation were inhibited by 2-deoxy-Dglucose and antimycin A (Table 2) . Metabolic inhibition blocked histamine release induced by anti-IgE, 1%, and almost completely blocked histamine release induced by substance P, 3 fiM and 30 pm, VIP, 3 pM, and somatostatin, 3 fM and 10pM.
The effects ofsubstance P antagonists on histamine release
A number of undecapeptide substance P analogues which antagonize tachykinin-induced smooth muscle contraction and which exhibit N-terminal homology with substance P have been shown to release histamine from rat mast cells (Foreman & Piotrowski, 1985) . Substitution of D-Phe or D-Trp residues in the C-terminal sequence of substance P is known to increase the histamine releasing activity of the peptide. The effect of one such analogue, [D-Pro2,r-Trp7'9] substance P was assessed on human skin mast cells in the concentration range 0.1 iM to 30 pim.
In four experiments, histamine release was significantly greater than spontaneous at 0.1 m, being 1.9 + 0.6%, and increased in a concentration-related manner from 4.0 + 0.9% and 6.2 + 1.2% at 0.3 yM and 1 yM to a maximum of 9.7 + 1.4% at 30pM. In the same experiments histamine release induced by substance P was significantly greater than sponta-neous at 1 ym, being 1.7 + 0.4%, and increased in a concentration-related manner to a maximum of 10.4 + 1.1% at 30upM. At a response level corresponding to 5% net histamine release [D-Pro2,D-Trp7'9] SP was 7.2 times more potent than substance P. [D-Pro2,D-Trp7'9] SP was, therefore, a more potent secretagogue than substance P but had the same maximal effect. Another analogue, [D-Pro4, D-Trp7'9 10] SP4-11 (SPA), although substituted with D-Trp residues in the C-terminal sequence, lacks the N-terminal homology with substance P required for histamine releasing activity. In four experiments, SPA did not induce significant histamine release from human skin mast cells in the concentration range 0.3 ym to 30 pM.
As SPA has been reported to antagonize both substance P-induced histamine release from rat mast cells and substance P-induced flare in human skin (Foreman & Piotrowski, 1985) , we tested the ability of SPA to inhibit substance P-induced histamine release from human skin mast cells (Figure 4) . In four experiments, increasing concentrations of SPA in the range 0.3 ym to 30gM produced a graded shift to the right of the substance P concentrationresponse curve for histamine release. Histamine release induced by substance P. 30jM, was inhibited by 18.2 + 3.0% (P < 0.05), 50.0 + 9.0% (P < 0.05) and 74.3 + 6.0% (P < 0.01) in the presence of SPA, 3pM, 10pM and 30gM respectively. In contrast to SPA, substance P fragment 4-11, 30gM, had no sig- nificant effect on histamine release induced by substance P, 1MM to 30Mm, in three experiments. A further three experiments showed that neurotensin, which antagonizes substance P-induced histamine release from rat mast cells and flare in human skin , had no significant effect on histamine release from human skin mast cells induced by substance P. 1 Mm to 30Mm, when present at 30MM.
In addition to inhibiting substance P-induced histamine release, SPA, 30yM, also inhibited histamine release induced by VIP, somatostatin and several other non-immunological secretogogues ( Figure 5 ) which we have previously found to induce calciumindependent histamine release from human mast cells (Benyon et al., 1987) . In three experiments, histamine release induced by VIP, 1OMM, was reduced by SPA from 11.4 + 2.6% to 6.3 + 2.3%, a reduction of 48.8 + 10.4% (P < 0.01). In five experiments, histamine release induced by somatostatin, lOpM, was reduced by SPA from 10.4 + 2.8% to 7.1 + 2.0%, a reduction of 32.5 + 2.8% (P < 0.05).
In these experiments, as a positive control, histamine release induced by substance P. lOyM, was reduced from 9.4 + 2.9% to 5.6 2.1% in the presence of SPA, a reduction of 46.0 + 13.4% (P < 0.05). Inhibition by SPA was specific for non-immunological secretagogues as in five experiments histamine release induced by anti-IgE, 0.1%, 0.3% and 1%, was not significantly affected by the presence of SPA, 30 Mm. Histamine release in the absence and presence of SPA was 13.0 + 5.8% and 13.3 ± 2.8%, 17.9 + 5.6% and 15.8 + 2.8%, and 19.6 + 6.1% and 17.3 + 3.3% respectively. Histamine release induced by compound 48/80, lOjUgmI 1, POIY-L-lysine, 1pOM, and morphine, 30pM, was also inhibited in the presence of SPA, 30pM, by 82.4 + 6.7% (P < 0.01), 80.1 + 8.6% (P < 0.02) and 79.5 + 11.5% (P < 0.05) respectively. In this series of experiments, histamine release induced by substance P. 10pM, used as a positive control, was inhibited by 85.7 + 5.1%
(P < 0.01) in the presence of 30pM SPA.
Discussion
In this study we have demonstrated that substance P. VIP and somatostatin release histamine from human dispersed skin mast cells with characteristics similar to those previously described for rat mast cells (Shanahan et al., 1985) . Histamine release from human skin mast cells induced by these peptides is concentration-related over the range 1 Mm to 30MM.
Although cytotoxicity may be suspected at these high concentrations of secretagogue, blockade of his-tamine release by inhibition of glycolysis and oxidative phosphorylation strongly suggests a non-cytotoxic, energy-requiring process. This conclusion is further supported by the observation that histamine secretion is inhibited by SPA. The time course of neuropeptide-induced histamine release from skin mast cells is rapid, being complete within 30s. This is much faster than substance P-induced histamine release demonstrable in vitro from human skin slices where physical barriers to diffusion of both peptide and histamine may give a false time course of mast cell activation (Ebertz et al., 1987) . Removal of extracellular calcium reduces substance P-induced histamine release by < 50% and has little effect on histamine release induced by VIP or somatostatin, indicating that these secretagogues may activate secretion either by mobilization of intracellular calcium or by a calcium-independent mechanism. These findings are similar to those in rat peritoneal mast cells where absence of extracellular calcium does not inhibit histamine release induced by substance P, VIP or somatostatin. Depletion of intracellular calcium by prolonged incubation of rat peritoneal mast cells with EDTA does, however, lead to a 70 to 80% reduction in histamine release (Shanahan et al., 1985) . The low histamine releasing activity of physalaemin, eledoisin, neurokinin A and neurokinin B relative to substance P suggests that the human skin mast cell activation site is a receptor distinct from the tachykinin NK-1, NK-2 or NK-3 types previously described (Lee et al., 1986) . Our finding that step-wise removal of N-terminal amino acids of substance P progressively reduces histamine releasing activity supports the hypothesis that the integrity of this portion of the molecule is important for releasing activity. Nonetheless, the inactivity of SP, 4 alone, and the increased potency of [D-Pro2,D-Trp7'9] SP, suggests that the C-terminal sequence does have some role in the full expression of activity, possibly increasing the lipophilicity of the peptides (Fewtrell et al., 1982) .
In terms of time course and calcium dependency, histamine release from human skin mast cells induced by substance P, VIP and somatostatin is similar to that previously described for compound 48/80, poly-L-lysine and morphine (Benyon et al., 1987) . Furthermore, relatively high concentrations of each secretagogue are required to induce 15-20% histamine release. Our results show [D-Pro4,D-Trp7'9'10] SP4-11 (SPA) to be an antagonist of substance P-induced histamine release from human skin mast cells and to have similar potency in inhibiting histamine release induced by VIP, somatostatin compound 48/80, poly-L-lysine and morphine. This suggests that these stimuli share a common pathway of activation-secretion coupling, possibly acting via a common cell-surface activation site of low affinity and poor specificity. A similar activation site may exist on rat peritoneal mast cells and our findings are consistent with studies showing histamine release from these cells in response to substance P. VIP and somatostatin to be inhibited by SPA (Foreman & Piotrowski, 1985) . The activation mechanism employed by substance P, VIP and somatostatin in human skin mast cells appears to be distinct from that for IgE-dependent stimuli. Histamine release in response to anti-IgE is relatively slow, reaching a maximum after 7-10min (Benyon et al., 1987) , is totally dependent on extracellular calcium, and is not significantly inhibited by SPA. There are also differences in the spectrum of mediators released by IgE-dependent and non-immunological stimuli, with anti-IgE being far more effective than substance P as a generator of prostaglandin D2 and leukotriene C4 (Benyon, Robinson & Church, unpublished observations) . The ability of human skin mast cells to release histamine in response to substance P, VIP and somatostatin is consistent with in vivo findings in human skin where intradermal injection of each of these neuropeptides induces weal and flare reactions (Anand et al., 1983) . The flare, or vasodilatory, component of such reactions is considered to be mediated by histamine, being inhibited by H1-histamine antagonists (Hagermark et al., 1978) , is neurogenic, being inhibited by nerve section, prior application of local anaesthetics and depletion of peripheral nerve neuropeptide content by capsaicin (Bayliss, 1901; Foreman et al., 1983; Anand et al., 1983) , and therefore is thought to involve an interaction between skin mast cells and neuropeptides (Hagermark et al., 1978; Foreman et al., 1983) . Calcitonin gene-related peptide and neurotensin, which we have shown to be poor histamine releasers from human skin mast cells, are much less potent than substance P in inducing both weal and flare reactions in human skin and histamine release from rat peritoneal mast cells Piotrowski & Foreman, 1986 ). Although at low doses CGRP does produce local vasodilatation, and pronounced long-lasting erythema, these are not associated with a characteristic weal and flare reaction and are not thought to result from a direct action of CGRP on skin mast cells (Brain et al., 1986; Piotrowski & Foreman, 1986) .
Whether or not neuropeptide-induced activation of human skin mast cells has a physiological function is uncertain but there is increasing evidence that neuropeptides, acting via receptors on immune effector cells, can modulate a range of immunological responses Payan et al., 1984; Goetzl et al., 1985) . A role for neuropeptides in both negative and positive feedback mechanisms regulating mediator release from immune cells is suggested by the presence of somatostatin-like peptides in rat basophilic leukaemia (RBL) cells (Goetzl et al., 1985) and VIP immunoreactivity in rat peritoneal mast cells (Cutz et al., 1978) . Somatostatin-like peptides from RBL cells appear to inhibit mediator release from these cells whereas VIP immunoreactivity, which is released from rat peritoneal mast cells in response to compound 48/80, may stimulate further mast cell mediator release.
In conclusion, we have demonstrated that human dispersed skin mast cells release histamine in response to substance P, VIP and somatostatin. The similarity of this response to that for compound 48/80, poly-L-lysine and morphine, and inhibition of the response to each secretagogue by a substance P antagonist, suggest that they share a common pathway of activation-secretion coupling distinct from that of IgE-dependent activation. Human skin mast cells are distinct from other human mast cells so far studied in their ability to respond to basic, non-immunological stimuli (Lowman et al., 1988) and this may well reflect a specialized function for these cells. M.A.L. is in receipt of a SERC-CASE studentship in collaboration with Roussel Laboratories. R.C.B. is supported by the Medical Research Council. We thank the surgeons and staff of Southampton General Hospital for provision of skin specimens. We are grateful to Ms Dianne Wilson for typing this manuscript.
